{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:03:40Z","timestamp":1792296220076,"version":"4.4.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In patients with phyllodes tumors of the breast, the presence of mediator of RNA polymerase II transcription subunit 12 homolog mutations (MED12m) and a history of previous fibroadenoma may predict better outcomes. To aid in the prognostication of malignant phyllodes tumors of the breast (B-MPT), we assessed the prognostic value of fibroadenoma-like areas (supposed to have stemmed from a pre-existing fibroadenoma) and MED12m, in patients with resected primary B-MPTs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-center, retrospective, cohort study including all consecutive patients aged \u226518 years old, with non-metastatic B-MPT, who underwent surgery from January 2000 to December 2021. The endpoints were the cumulative incidences of all recurrences, according to the presence of fibroadenoma-like areas, reviewed by 3 reference pathologists. A nested, case-control genomic analysis was performed to evaluate the association between MED12m, the presence of fibroadenoma-like areas, and cancer recurrences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eight-nine patients were included, with 47% of tumors exhibiting Fibroadenoma-Like Areas (FLA+). These areas were not significantly associated with local recurrence (5-year cumulative incidence in FLA+ vs FLA-: 13.0, 95%CI [4.6-25.9] vs 23.6, 95%CI [11.9-37.5]; P\u2005=\u2005.14) or distant recurrence (5-year cumulative incidence in FLA+ vs FLA-: 12.5, 95%CI [4.5-25.0] vs 8.9, 95%CI [2.8-19.5], P\u2005=\u2005.61), at a median follow-up of 6.7 years. MED12m was not associated with distant recurrences or the presence of fibroadenoma-like areas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Half of B-MPTs are characterized by the presence of fibroadenoma-like areas. This pathologic feature is not significantly associated with lower distant and local recurrences nor with the presence of MED12 mutations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf012","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T11:30:34Z","timestamp":1737113434000},"source":"Crossref","is-referenced-by-count":4,"title":["The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis"],"prefix":"10.1093","volume":"30","author":[{"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]},{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]},{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Porta","sequence":"additional","affiliation":[{"name":"Division of Pathology, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Olmeda","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]},{"name":"Division of Pathology, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Gaeta","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]},{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Conversano","sequence":"additional","affiliation":[{"name":"Division of Pathology, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso Martino","family":"De Pas","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Cliniche Humanitas Gavazzeni , Bergamo 24125 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Castellano","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]},{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Santoro","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]},{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Battaiotto","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]},{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltjona","family":"Mane","sequence":"additional","affiliation":[{"name":"Division of Pathology, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Coppola","sequence":"additional","affiliation":[{"name":"Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Conforti","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Cliniche Humanitas Gavazzeni , Bergamo 24125 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Mattar","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Veronesi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]},{"name":"Division of Breast Surgery, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Guerini Rocco","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]},{"name":"Division of Pathology, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Pennacchioli","sequence":"additional","affiliation":[{"name":"Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan 20141 ,","place":["Italy"]},{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"2025030422473734700_CIT0001","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.critrevonc.2013.06.005","article-title":"Breast phyllodes tumor: a review of literature and a single center retrospective series analysis","volume":"88","author":"Spitaleri","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025030422473734700_CIT0002","doi-asserted-by":"publisher","first-page":"113423","DOI":"10.1016\/j.ejca.2023.113423","article-title":"Primary malignant phyllodes tumors of the breast: a retrospective analysis from a referral center","volume":"196","author":"Valenza","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025030422473734700_CIT0003","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1524-4741.2007.00510.x","article-title":"Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast","volume":"13","author":"Morales-V\u00e1squez","year":"2007","journal-title":"Breast J."},{"key":"2025030422473734700_CIT0004","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12282-009-0185-x","article-title":"Malignant transformation of breast fibroadenoma to malignant phyllodes tumor: long-term outcome of 36 malignant phyllodes tumors","volume":"18","author":"Abe","year":"2011","journal-title":"Breast Cancer."},{"key":"2025030422473734700_CIT0005","doi-asserted-by":"publisher","first-page":"e000843","DOI":"10.1136\/esmoopen-2020-000843","article-title":"Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases","volume":"5","author":"Di Liso","year":"2020","journal-title":"ESMO Open."},{"key":"2025030422473734700_CIT0006","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/jclinpath-2015-202896","article-title":"MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases","volume":"68","author":"Ng","year":"2015","journal-title":"J Clin Pathol."},{"key":"2025030422473734700_CIT0007","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41523-017-0042-6","article-title":"Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways","volume":"3","author":"Pareja","year":"2017","journal-title":"NPJ Breast Cancer."},{"key":"2025030422473734700_CIT0008","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.3390\/cancers13205230","article-title":"OncomineTM comprehensive assay v3 vs. OncomineTM comprehensive assay plus","volume":"13","author":"Vestergaard","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025030422473734700_CIT0009","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc."},{"key":"2025030422473734700_CIT0010","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat."},{"key":"2025030422473734700_CIT0011","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1158\/1541-7786.MCR-14-0578","article-title":"Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors","volume":"13","author":"Cani","year":"2015","journal-title":"Mol Cancer Res"},{"key":"2025030422473734700_CIT0012","doi-asserted-by":"publisher","first-page":"P2","DOI":"10.1158\/1538-7445.sabcs22-p2-23-03","article-title":"Abstract P2-23-03: genomic evaluation of malignant phyllodes tumors reveals multiple targetable opportunities","volume":"83","author":"Rosenberger","year":"2023","journal-title":"Cancer Res"},{"key":"2025030422473734700_CIT0013","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1093\/oncolo\/oyae218","article-title":"Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities","volume":"29","author":"Rosenberger","year":"2024","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyaf012\/61807820\/oyaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyaf012\/61807820\/oyaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T22:48:06Z","timestamp":1741128486000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf012\/8005522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf012","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]},"article-number":"oyaf012"}}